Search Results

You are looking at 41 - 50 of 2,919 items for :

  • Refine by Access: All x
Clear All
Full access

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

Background Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. 1 Although ICIs have improved outcomes in several cancers, their use is also

Full access

Pilot Randomized Controlled Trial of an Educational Video for CAR T-Cell Therapy Recipients

P. Connor Johnson, Tejaswini Dhawale, Richard A. Newcomb, Ana Barata, Kyle Karpinski, Mitchell W. Lavoie, Dagny Vaughn, Kathleen Hennessey, David Schneider, Hermioni L. Amonoo, Angelo Volandes, and Areej El-Jawahri

no), and clinical diagnosis of anxiety and/or depression (yes vs no). Specifics about self-reported measures are summarized in the “Data Collection and Study Outcomes” section. After study enrollment and completion of the baseline questionnaire

Full access

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group*

-wide association studies associated with increased risk for hypogonadism. 11 No study, however, has examined the prevalence of hypogonadism in North American TCS and its relationship to adverse health outcomes (AHOs). Most TCS have had one testicle (or both

Full access

Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity

Fawaz Mayez Mahfouz, Tiffany Li, Hannah C. Timmins, Lisa G. Horvath, Michelle Harrison, Peter Grimison, Gavin Marx, David Goldstein, and Susanna B. Park

of neuropathy severity, 13 which does not include neuropathic pain. Further, few patient-reported outcome measures (PROMs) for CIPN evaluation focus on identifying pain and its impact. 12 The aim of this study was to understand the differences in

Full access

Do Outcomes in Elective Colon and Rectal Cancer Surgery Differ by Weekday? An Observational Study Using Data From the Dutch ColoRectal Audit

Daniëlle D. Huijts, Onno R. Guicherit, Jan Willem T. Dekker, Julia T. van Groningen, Leti van Bodegom-Vos, Esther Bastiaannet, Johannes A. Govaert, Michel W. Wouters, and Perla J. Marang-van de Mheen

performed on a Friday. However, these studies showing worse outcomes after Friday surgeries may be limited because of their use of administrative data, which are known to be susceptible to insufficient adjustment for case mix. 9 As a result, worse outcomes

Full access

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia

ribociclib and subsequently received abemaciclib-based therapy. We report on the treatment patterns of continued CDK4/6i therapy across 6 institutions, the clinical outcome data, the toxicity experience with a second course of CDK4/6i, and emerging insights

Full access

Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer

Ryan D. Nipp, Brandon Temel, Charn-Xin Fuh, Paul Kay, Sophia Landay, Daniel Lage, Esteban Franco-Garcia, Erin Scott, Erin Stevens, Terrence O’Malley, Supriya Mohile, William Dale, Lara Traeger, Ardeshir Z. Hashmi, Vicki Jackson, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

population accounts for nearly three-fourths of cancer deaths. 1 Older adults diagnosed with cancer also experience worse survival outcomes than their younger counterparts, which may result from differential treatment of the geriatric cancer population. 2

Full access

Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma

Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou

the role of PORT in survival outcome, which would help surgeons and radiologists provide individualized recommendations regarding PORT to patients with ACC. Patients and Methods Patient Characteristics From January 2000 through December 2017, 480

Full access

Magnitude of the Age-Advancement Effect of Comorbidities in Colorectal Cancer Prognosis

Daniel Boakye, Viola Walter, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

recurrence-related outcomes is limited. It is also unclear whether the impact of comorbidities varies by tumor stage or site. In some previous studies, the effect of comorbidity on overall survival (OS) appeared to be more pronounced in patients with early

Full access

Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

currently accepted framework for quality measurement in oncology, in part based on the structure, process, and outcome model for assessment of healthcare quality defined in the 1960s by Avedis Donabedian. 2 Shortly thereafter, the National Quality Forum